Navigating dual compliance: Manufacturers’ obligations under the EU AI Act and MDR for AI systems
Abstract
This paper analyses manufacturers’ dual obligations under the European Union (EU) AI Act and Medical Device Regulation (MDR). It shows that divergent classification rules generate parallel high-risk pathways, that post-market surveillance regimes differ in scope and mechanics, and that human oversight duties remain undefined in audit-ready, clinical terms. Friction is most acute in continuously learning models, where the MDR’s static clinical evaluation assumptions collide with the AI Act’s demand for ongoing validation. These conflicts increase compliance costs, delay market access and favour incumbents. The paper recommends procedural harmonisation: joint guidance, integrated conformity workstreams, explicit thresholds for model updates, auditable oversight controls and interoperable monitoring systems. It concludes that coordinated supervisory practice and compliance-by-design governance are the most workable means of aligning device safety with artificial intelligence (AI)-specific risk management. This article is also included in The Business & Management Collection which can be accessed at https://hstalks.com/business/.
The full article is available to subscribers to the journal.
Author's Biography
Sean Musch is the Chief Executive Officer (CEO) and Founder, AI & Partners. Sean is a seasoned expert in artificial intelligence (AI regulation), specialising in the European Union (EU) AI Act and its implications for global technology companies. With over a decade of experience in the professional services sector, Sean has advised multinational enterprises on compliance, risk management and regulatory frameworks related to AI. His background as a tech accountant, where he navigated complex financial and compliance landscapes, included assisting with an initial public offering (IPO) on the New York Stock Exchange. Sean also has deep expertise in audit and assurance, working with the world’s largest tech multinational enterprises (MNEs) to implement regulatory strategies effectively. In addition to his regulatory acumen, Sean has an extensive background in the entertainment industry, particularly in film, art and design, giving him a unique perspective on the intersection of AI, creativity and compliance.
Michael Borrelli is the Director of AI & Partners. As a leading expert in artificial intelligence (AI) regulation and risk, Michael provides strategic guidance to businesses operating at the intersection of AI, Web3 and financial services. Michael specialises in helping organisations align with fast-evolving laws such as the EU AI Act and build responsible AI governance frameworks that drive innovation while managing compliance and risk. With over a decade of experience advising Financial Conduct Authority (FCA)-regulated companies and institutional financial services providers, Michael supports organisations in understanding complex regulatory environments, operationalising compliance and embedding ethical AI practices into their core strategy.
Charles Kerrigan, Partner, CMS UK, is a specialist in emerging technologies including crypto, digital assets, Web3 and artificial intelligence (AI). His areas of interest include corporate finance and venture capital transactions in crypto, tokenisation, NFTs, Web3 and DeFi. He works on consulting projects on blockchain and AI for public bodies, policy makers, standards institutions and corporations. The Blockchain Industry in the UK Landscape Overview names Charles as a ‘leading influencer in blockchain’. He is part of teams working on investing and setting standards for EmTech in the UK, Europe and the US. At CMS he is a Partner in a team that covers EmTech. Charles has roles on the advisory boards of AI and crypto companies and of trade bodies. He is the Editor and co-author of AI Law and Regulation (Edward Elgar, 2022) and the Contributing Editor of AI, Machine Learning & Big Data (GLI, 2023). In 2022, Charles was listed in The Lawyer Hot 100 of ‘most daring, innovative and creative lawyers’.
Eva Dias Costa is Associate Professor of Law at Portucalense University, where she coordinates the Unit of the International Chair in Bioethics, and of counsel at CNMF law firm in Porto, Portugal. She completed her postgraduate studies in bioethics at the Faculty of Medicine, University of Porto, where she is also a member of the Bioethics Centre. Eva trained at the Harvard T. H. Chan School of Public Health (PPCR). Her work focuses on health law, clinical research ethics and the regulation of emerging technologies. She collaborates with AI & Partners on the ethical and legal dimensions of artificial intelligence (AI) governance in healthcare.